Pharmacogenetic studies investigating the adverse effects of antipsychotics

Psychiatry Investigation

Volumn 4, Issue 2, 2007, Pages 66-75

  Lee, Heon Jeong ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Adverse effects; Antipsychotics; Pharmacogenetics; Tardive dyskinesia; Weight gain

Indexed keywords

ACYLTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DNA; MYELOPEROXIDASE; OLANZAPINE; RISPERIDONE; THIOPURINE METHYLTRANSFERASE; ZIPRASIDONE;

AGRANULOCYTOSIS; ALLELE; CHROMOSOME 12Q; CHROMOSOME 14Q; CHROMOSOME 20P; CHROMOSOME 2Q; CHROMOSOME 9P; DNA MICROARRAY; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME METABOLISM; ETHNIC DIFFERENCE; GENE DUPLICATION; GENE LOCUS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACOGENETICS; RECEPTOR GENE; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TARDIVE DYSKINESIA; THERMOGENESIS; TREATMENT DURATION; WEIGHT GAIN;

EID: 35348959536     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
2. Kerwin RW, Osborne S. Antipsychotic drugs. Medicine 2000;28:23-25.
3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-460.
4. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108.
5. McCombs JS, Nichol MD, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60 (suppl 19):5-11.
6. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000;61:124-135.
7. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol 1996;23:983-985.
8. Ingelman-Sundberg M, Johansson I, Persson I, Oscarson M, Hu Y, Bertilsson L, et al. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. EXS 1994;71:197-207.
9. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-243.
10. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50:31-34.
11. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotypc of drug response. Mol Psychiatry 2004;9:442-473.
12. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, et al. Risperidone plasma levels, clinical response and sideeffects. Eur Arch Psychiatry Clin Neurosci 2005;255:261-268.
13. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
14. Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20:71-78.
15. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-446.
16. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-666.
17. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C - >A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-449.
18. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, et al. Six novel nonsynony mous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308:300-306.
19. Kootstra-Ros JE, Smallegoor W, van der WJ. The cytochrome P450 CYP1A2 genetic polymorphisms *IF and *ID do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005;42:216-219.
20. Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C - >A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001;21:603-607.
21. Eap CB, Bender S, Jaquenoud SE, Cucchia G, Jonzier-Percy M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214-219.
22. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-831.
23. Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999;19:491-510.
24. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-113.
25. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004;14:813-822.
26. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006;6:277-826.
27. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett 2006;162:16-28.
28. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200.
29. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21 (suppl 2):106-115.
30. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990;102:474-478.
31. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618-1619.
32. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431-450.
33. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994:55 (suppl B):47-52.
34. Casey DE, Gerlach J, Magclund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376-1379.
35. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525-541.
36. Chen CH, Wei FU, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-829.
37. Chong SA, Tan EC, Tan CH, Mythily, Chan YH. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;11631-54.
38. Lee HJ, Choi JE, Kang SG, Kim L. Polymorphic variations in GSTM1, GSTT1, GSTP1, dopamine D2 and D3 receptors and their association with tardive dyskinesia in chronic schizophrenia. Psychiatry Invest 2007;4(suppl 1):121.
39. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996;93:1945-1949.
40. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
41. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-145.
42. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247-253.
43. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
44. Rietsehel M, Krauss H, Müller DJ, Schulze TG, Knapp M, Marwinski K, et al. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250:31-35.
45. Bakker PR, van Harten PN, Van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a metaanalysis. Schizophr Res 2006;83:185-192.
46. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004;7:489-493.
47. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M, et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3:277-283.
48. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111-117.
49. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor (DRD4) gene -521 CT polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007;55:47-51.
50. Matsumoto C, Shinkai T, Hori H, Ohmori O, Nakamura J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004;127:1-7.
51. Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001;50:144-147.
52. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6:225-229.
53. Herken H, Erdal ME, Boke O, Savas HA. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003;18:77-81.
54. Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001;6:230-234.
55. Deshpande SN, Vanna PG, Semwal P, Rao AR, Bhatia T, Nimgaonkar VL, et al. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005;15:157-158.
56. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005;8:411-425.
57. Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002;7:670-671.
58. Rietschel M, Naber D, Fimmers R, Moller HJ, Propping P, Nothen MM. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997;8:1999-2003.
59. Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of 5-HT (6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002;110:97-102.
60. Chong SA, Tan EC, Tan CH, Mahendren R, Tay AH, Chua HC. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 2000;96:712-715.
61. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998;71:1002-1012.
62. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-539.
63. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-1213.
64. Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868-872.
65. Kang SG, Lee HJ, Choi JE, Kim L. No evidence of association between glutathione S-transferase M1, T1 and P1 polymorphisms and tardive dyskinesia, in submission.
66. Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002;36:317-324.
67. Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, et al. Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet 2004;14:147-150.
68. Shinkai T, Müller DJ, De Luca V, Shaikh S, Matsumoto C, Hwang R, et al. Genetic association analysis of the glutathione peroxidase (GP-X1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res 2006;141:123-128.
69. Shinkai T, Ohmori O, Matsumoto C, Hori H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med 2004;5:163-170.
70. Hori H, Shinkai I, Matsumoto C, Ohmori O, Nakamura J. No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia. Neuromolecular Med 2006;8:375-380.
71. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Jun TY, et al. Quinone oxidoreduetase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004;7:495-500.
72. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-456.
73. Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D. A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clin Neuropharmacol 2005;28:285-288.
74. Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes. Schizophr Res 2007;92278-279.
75. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-216.
76. Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006;27:328-332.
77. Schillevoort I, de Boer A, van der WJ, Steijns LS, Roos RA, Jansen PA, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002;12:235-240.
78. Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, Liao DL, et al. Cytochrome P-450 2D6*10 C188 T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004;49:167-173.
79. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000;5:410-417.
80. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005;75:21-26.
81. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-456.
82. Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007, in press.
83. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
84. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-432.
85. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 200424 (5 suppl 1):7-14.
86. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359:2086-2087.
87. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000;43:373-376.
88. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001;62(suppl 23):45-66.
89. Zhang ZJ, Yao ZJ, Mou XD, Chen JF, Zhuk RX, Liu W, et al. Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Zhonghua Yi Xue Za Zhi 2003;83:2119-2123.
90. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15:195-200.
91. Reynolds GP, Zhang ZJ, Zhang XB. Polymorphism of the promoter region of the serotonin 5-HT (2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677-679.
92. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O'donovan MC. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005;162:613-615.
93. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134:76-78.
94. Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001;11:265-268.
95. Tsai SJ, Hong CJ, Yu YW, Lin CH. 759C/T genetic variation of 5HT (2C) receptor and clozapine-induced weight gain. Lancet 2002;360:1790.
96. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360:1790-1791.
97. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004;14:139-142.
98. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a metaanalysis. Int J Neuropsychopharmacol 2007;10:697-704.
99. Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:673-677.
100. Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Lee HJ. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients, in submission
101. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
102. Gong DW, Bi S, Pratley RE, Weintraub BD. Genomic structure and promoter analysis of the human obese gene. J Biol Chem 1996;271:3971-3974.
103. Mammes O, Betoulle D, Aubert R, Herbeth B, Siest G, Fumeron F. Association of the G-2548A polymorphism in the 50 region of the LEP gene with overweight. Ann Hum Genet 2000;64:391-394.
104. Li WD, Reed DR, Lee JH, Xu W, Kilker RL, Sodam BR, et al. Sequence variants in the 5′ flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet 1999;63:227-234.
105. Wang TN, Huang MC, Chang WT, Ko AM, Tsai EM, Liu CS, et al. G-2548A polymorphism of the leptin gene is correlated with extreme obesity in Taiwanese aborigines. Obesity 2006;14:183-187.
106. Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS. Association Study of-2548A/G Polymorphism of Leptin Gene with Antipsyhotics-Induced Weight Gain. Korean J Psychopharmacol 2006;17: 23-428.
107. Kang SG, Lee HJ, Park YM, CHoi JE, Han C, Kim YK, et al. Possible-association between the -2548A/G polymorphism of leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry, in press.
108. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Polymorphism of the adrenergic receptor alpha 2a -129IC>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005;112:1463-1468.
109. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, et al. Weight gain associated with the alpha2a-adrencrgic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006;141:394-397.
110. Tsai SJ, Yu YW, Lin CH, Wang YC, Chen JY, Hong CJ. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004;50:37-40.
111. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005;15:743-748.
112. Bishop JR, Ellingrod VL, Moline J, Miller D. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006;12:BR47-BR50.
113. Park YM, Lee HJ, Chung YC, Lee SH, Kang SG, Choi JE, et al. No evidence of association between G-protein beta subunit gene polymorphism and olanzapine-induce weight gain, in submission.
114. Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004;9:1067-1074.
115. Basile V, Masellis M, Ozdemir V, Quiterio S, Meltzer HY, Lieberman J, et al. Novel histamin H1 gene polymorphism and clozapine-induced weight gain. Am J Med Genet 2001;96:539.
116. Allen R, Hening WA, Montplaiser J, Walters AS, Brown T, Myers A. Restless legs syndrome (RLS), a common disorder rarely diagnosed in Europe or USA: the REST (RLS epidemiology, symptoms and treatment) study in primary care. Mov Disord 2002;17:S240.
117. Kim JY, Choi C, Shin K, Yi H, Park M, Cho N, et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry and Clin Neurosci 2005;59:350-353.
118. Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1078-1083.
119. Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003;126:1485-1492.
120. Chen S, Ondo WG, Rao S, Li L, Chen Q, Wang Q. Genomewide linkage scan identifies a novel susceptibility locus for RLS on chromosome 9p. Am J Hum Genet 2004;74:876-889.
121. Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau G. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12 q. Am J Hum Genet 2001;69:1266-1270.
122. Desautels A, Turecki G, Montplaisir J, Xiong L, Walters AS, Ehrenberg BL, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005;62:591-596.
123. Levchenko A, Montplaisir JY, Dube MP, Riviere JB, St-Onge J, Turecki G, et al. The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 2004;55:887-891.
124. Pichler I, Marroni F, Volpato CB, Gusella JF, Klein C, Casari G, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 2006;79:716-723.
125. Levchenko A, Provost S, Montplaisir JY, Xiong L, St-Onge J, Thibodeau P, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006;67:900-901.
126. Desautels A, Turecki G, Montplaisir J, Ftouhi-Paquin N, Michaud M, Chouinard VA, et al. Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology 2001;57:1304-1306.
127. Desautels A, Turecki G, Montplaisir J, Briscbois K, Sequeira A, Adam B, et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 2002;59:215-219.
128. Kang SG, Lee HJ, Choi JE, Park JH, Lee SS, Han C, et al. Possible association between G-protein beta3 C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, in press.
129. Kang SG, Lee HJ, Choi JE, Park JH, Han C, Kim YK, et al. Association study between antipsychotics-induccd restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia, in submission.
130. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576-580.
131. Amar A, Segman RH, Shtrussberg S, Sherman L, Safirman C, Lerer B, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998;1:141-44.
132. Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, et al. HLA-B38 and clozapine-induced agranulotycosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998;25:11-13.
133. Dettling M, Cascorbi I. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 2001;58:93-94.
134. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-617.
135. Ostrousky O, Meged S, Loewenthal R, Valevski A, Weizman A, Carp H, et al. NQO2 gene is associated jwith clozapine-induced agranulocytosis. Tissue Antigens 2003;62:483-491.
136. Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, et al. Tumor necrosis factor constellation polymorphism and clozapin-induced agranulocytosis in two different ethnic groups. Blood 1997;89:4167-4174.
137. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005;5:149-160.
138. Flomen R, Knight J, Sham P, Kerwin R, Makoff A. Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. Nucleic Acids Res 2004;32:2113-2122.
139. Petronis A. Epigenetics and twins: three variations on the theme. Trends Genet 2006;22:347-350.
140. Pozzi L, Hakansson K, Usiello A, Borgkvist A, Lindskog M, Grecngard P, et al. Opposite regulation by typical and atypical anti-psychotics of ERK1/2. CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 2003;86451-459.